Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharmaceuticals crawled time : 12:20 save search
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Published: 2023-08-16 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 6.57%
H: 0.0%
C: 0.0%
diarrhea indicate world sclerosis treatment pharmaceuticals potential
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-08-14 (Crawled : 12:20) - globenewswire.com
ELOX | $0.94 -51.57% 93K
|
Health Technology
|
| O: 5.05%
H: 20.04%
C: 14.83%
business update pharmaceuticals financial results
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Published: 2023-08-14 (Crawled : 12:20) - biospace.com/
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: -2.46%
H: 2.53%
C: -10.61%
pharmaceuticals financial results
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
Published: 2023-08-10 (Crawled : 12:20) - biospace.com/
MIST | $1.64 0.61% 0.61% 30K
|
Health Technology
|
| O: 2.56%
H: 4.06%
C: 3.12%
update pharmaceuticals financial results milestone
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
Published: 2023-08-10 (Crawled : 12:20) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K
|
Health Technology
|
| O: -2.36%
H: 2.84%
C: 1.33%
pharmaceuticals financial results
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Published: 2023-08-10 (Crawled : 12:20) - globenewswire.com
HTGC F | $18.46 1.15% 0.38% 660K
|
Finance
|
| O: 0.47%
H: 0.0%
C: 0.0%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.46%
H: 4.74%
C: 3.26%
pharmaceuticals results
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
Published: 2023-08-08 (Crawled : 12:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.34%
H: 0.8%
C: -5.31%
PCSA M | $1.58 1.28% 1.27% 19K
|
Producer Manufacturing
|
| O: 2.44%
H: 0.02%
C: -7.14%
life pharmaceuticals sciences
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float
Published: 2023-08-04 (Crawled : 12:20) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 6.04%
H: 0.04%
C: -9.04%
pharmaceuticals
Universe Pharmaceuticals INC Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares
Published: 2023-08-04 (Crawled : 12:20) - globenewswire.com
UPC | $2.19 8.76% 95K
|
Manufacturing
|
| O: 2.81%
H: 0.55%
C: -9.37%
nasdaq pharmaceuticals market
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
VRCA | $6.96 0.87% 0.72% 130K
|
Health Technology
|
| O: -1.28%
H: 3.16%
C: -1.12%
vp-315 cell treatment pharmaceuticals
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
conference biotech pharmaceuticals
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
Published: 2023-08-02 (Crawled : 12:20) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: -18.47%
H: 63.27%
C: 3.91%
offering pharmaceuticals
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
Published: 2023-08-02 (Crawled : 12:20) - globenewswire.com
RVLP | $0.0282 -20.92% 64M
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -1.69%
update pharmaceuticals commercial financial results
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
Published: 2023-07-28 (Crawled : 12:20) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: -10.49%
H: 9.99%
C: -3.45%
zimhi opioid pharmaceuticals study
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Published: 2023-07-27 (Crawled : 12:20) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -3.21%
H: 2.51%
C: -0.44%
ADXS | $0.57 12.48% 9.5K
|
Health Technology
|
| O: 6.93%
H: 3.7%
C: 1.85%
pharmaceuticals agreement
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
Published: 2023-07-20 (Crawled : 12:20) - biospace.com/
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.06%
H: 1.21%
C: 0.17%
ASRT | $0.7625 1.13% 1.11% 890K
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: -1.3%
pharmaceuticals glass
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
Published: 2023-07-17 (Crawled : 12:20) - biospace.com/
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: -0.58%
H: 3.78%
C: 0.87%
clearance pharmaceuticals study
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: 3.45%
H: 0.01%
C: -15.33%
sp-3164 fda drug clearance pharmaceuticals application trial
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
Published: 2023-06-20 (Crawled : 12:20) - biospace.com/
MIST | $1.64 0.61% 0.61% 30K
|
Health Technology
|
| O: -0.86%
H: 3.75%
C: -0.86%
etripamil lancet rapid publication pharmaceuticals spray trial results milestone
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.